News | May 22, 2021
Balaxi records Q4 FY21 revenue of Rs. 53 Cr
Drop in revenue in the fourth quarter is normal as China is shut down for most of the quarter due to the Chinese New Year holiday
Drop in revenue in the fourth quarter is normal as China is shut down for most of the quarter due to the Chinese New Year holiday
Availability of drugs is being monitored by implementing a three-pronged strategy of supply chain management, demand side management, and affordability.
Targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses from the date of start of commercial production
Number of approved manufacturing sites of Remdesivir in the country has increased from 22 sites to 60
Natco has withdrawn its application filed with the Indian Patent Office, seeking Compulsory License against Lilly for Baricitinib for Covid-19 in India
The outlook for the US business remains good as respiratory pipeline (gAbraxane, gAdvair, gDulera) adds medium-term growth visibility.
India sales grew 23.5% YoY with consolidation of Wockhardt products
The company plans to aggressively invest in longer gestation period projects like innovation, biosimilars, vaccines, etc.
A total quantum of more than 4.39 crore doses was also available for direct procurement by the states as well as private hospitals in the month of May 2021
Financial support is being provided as a grant from the Government of India
Subscribe To Our Newsletter & Stay Updated
